ABSTRACT

Ayurvedic pharmaceutics deals with preparation and processing of metal and mineral based medicines. Bhasmikarana (incineration) is one such method to make the drug particles in nano scale aiming for better assimilation and bio-availability. Added on with such classical processing techniques, curating bhasmikarana along with mechanical size reduction techniques raises the question of greater bio- availability in lesser doses than recommended. Hence this paper attempted to evaluate the acute toxic effects of one such curated formula - Potentiated Yashada Bhasma (PYB) as a primary step in exploring the drug’s safety and efficacy following OECD guidelines 420 with five female wistar rats. After confirmation of nil effects in sighting study (2000 mg PYB/kg) on one animal, rest four animals were also given the same dose and observed for adverse effects at different time points up to 14 days. On 15th day blood was collected for haematological and biochemical evaluation and later all the animals were euthanized. Major organs were dissected and sent for histopathological examination. The results revealed slight alterations in the total WBC count, neutrophils, SGOT and total bilirubin levels. Histopathological findings showed mild to moderate congestion in all major organs along with slight inflammatory changes especially in kidney, brainand liver while symptomatically all the animals appeared completely normal at 2000mg/kg, which is almost ten times of therapeutic dose of Yashada bhasma. Thus, it can be concluded that PYB at 2000 mg/kg is found symptomatically safe in-spite of mild varied values with blood and histopathological investigations. However clinically this higher dose is very unlikely to occur, thus PYB can be considered safe. Keywords: Zinc oxide nano particles, yashada bhasma, safety, adverse effects, metallic medicines
Publication date: 01/12/2024

https://ijbpas.com/pdf/2024/December/MS_IJBPAS_2024_8557.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.12.8557